Clinical significances of the synchronous detection of mucin 1 and collagen Ⅳ in breast cancer by using quantum dots immunofluorescence imaging technique / 肿瘤研究与临床

ABSTRACT

Objective@#To investigate the relationship between the expression of mucin 1 and collagen Ⅳ and the clinical characteristics in invasive breast cancer by using the quantum dots immunofluorescence imaging technique.@*Methods@#The expressions of mucin 1 and collagen Ⅳ were detected simultaneously by quantum dots immunofluorescence imaging technique in 94 cases of breast cancer from July 2007 to July 2010 in Affiliated Hospital of Guilin Medical University. The correlation of mucin 1 and collagen Ⅳ quantitative parameters with clinicopathological features and the prognosis were also analyzed.@*Results@#The positive rates of mucin 1 in human breast cancer tissues marked by quantum dots immunofluorescence imaging technique and immunohistochemistry were 73.4 % (69/94) and 69.1 % (65/94), the positive rates of collagen Ⅳ were 53.2 % (50/94) and 47.9 % (45/94), and the differences were not statistically significant (both P > 0.05) Quantum dots immunofluorescence imaging technique was consistent with conventional immunohistochemistry (IHC) in detecting the expressions of mucin 1 and collagen Ⅳ in human breast cancer tissues (κ = 0.763, P = 0.000; κ=0.759, P = 0.000). The expression of mucin 1 was negatively correlated with collagen Ⅳ (r = -0.883, P < 0.01). The expressions of mucin 1 and collagen Ⅳ were respectively associated with tumor size (F = 3.683, P = 0.029; F = 4.922, P = 0.009), histological grading (F = 3.529, P = 0.033; F = 3.912, P = 0.023), lymph node metastasis (t = -4.868, P = 0.000; t = 3.868, P = 0.000), pathological stage (t = -8.337, P = 0.000; t = 5.962, P = 0.000) and 5-year disease free survival rate (both P = 0.000), and the differences were statistically significant (all P < 0.05).@*Conclusion@#The co-detection of mucin 1 and collagen Ⅳ by using quantum dots immunofluorescence imaging technique provides direct evidence determining the biologic behaviors of breast cancer and evaluating the prognosis.